Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

DSGN

Design Therapeutics Inc

Apr 18 • 04:00PM ET

3.74

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWN VTWO SCHA IWC ONEQ FESM VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.19	Insider Own	41.56%	Shs Outstand	56.47M	Perf Week	-0.80%
Market Cap	211.27M	Forward P/E	-	EPS next Y	-1.36	Insider Trans	0.12%	Shs Float	33.02M	Perf Month	44.40%
Income	-66.86M	PEG	-	EPS next Q	-0.27	Inst Own	44.69%	Short Float	6.76%	Perf Quarter	60.52%
Sales	0.00M	P/S	-	EPS this Y	0.84%	Inst Trans	3.11%	Short Ratio	8.72	Perf Half Y	70.00%
Book/sh	4.92	P/B	0.76	EPS next Y	-15.47%	ROA	-21.20%	Short Interest	2.23M	Perf Year	-28.08%
Cash/sh	4.99	P/C	0.75	EPS next 5Y	-	ROE	-22.10%	52W Range	1.94 - 8.47	Perf YTD	41.13%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-138.68%	ROI	-23.88%	52W High	-55.84%	Beta	1.80
Dividend TTM	-	Quick Ratio	29.58	Sales past 5Y	0.00%	Gross Margin	-	52W Low	92.78%	ATR (14)	0.27
Dividend Ex-Date	-	Current Ratio	29.58	EPS Y/Y TTM	-5.11%	Oper. Margin	0.00%	RSI (14)	56.61	Volatility	7.02% 9.35%
Employees	124	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	4.75
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	32.06%	Payout	-	Rel Volume	0.00	Prev Close	3.74
Sales Surprise	-	EPS Surprise	32.26%	Sales Q/Q	-	Earnings	Mar 19 AMC	Avg Volume	255.81K	Price	3.74
SMA20	-0.44%	SMA50	20.63%	SMA200	15.54%	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-23	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $6
Aug-15-23	Downgrade	Wedbush	Outperform → Neutral	$19 → $6
Aug-15-23	Downgrade	SVB Securities	Outperform → Market Perform	$6
Aug-15-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$23 → $7
May-04-23	Upgrade	Goldman	Sell → Neutral	$6
Jun-10-22	Initiated	Wedbush	Outperform	$21
May-02-22	Initiated	RBC Capital Mkts	Outperform	$30
Jan-19-22	Initiated	Goldman	Sell	$10
Apr-20-21	Initiated	SVB Leerink	Outperform	$36
Apr-20-21	Initiated	Piper Sandler	Overweight	$42
Apr-20-21	Initiated	Goldman	Neutral	$28

Show Previous Ratings

Mar-20-24 10:31AM	Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript (Insider Monkey) +11.97%
06:58AM	Q4 2023 Design Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:53PM	DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
05:33PM	Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress (GuruFocus.com)
04:01PM	Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
06:30AM	Loading…
Mar-12-24 06:30AM	Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update (GlobeNewswire)
Dec-18-23 12:00PM	Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update (GuruFocus.com) +11.71%
Nov-13-23 04:05PM	Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024 (GlobeNewswire)
Aug-15-23 03:02PM	Why Shares of Design Therapeutics Are Plummeting on Tuesday (Motley Fool) -70.46%
09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly)
02:34AM	4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi (Investing.com)
Aug-14-23 04:05PM	Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
04:01PM	Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia (GlobeNewswire)
Jun-18-23 08:03AM	Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \ (Simply Wall St.)
06:30AM	Loading…
May-31-23 06:30AM	Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) -6.01%
May-09-23 04:05PM	Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-08-23 06:05AM	We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely (Simply Wall St.)
Apr-24-23 06:30AM	Design Therapeutics to Present Preclinical Data on its GeneTAC Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023 (GlobeNewswire)
Apr-11-23 09:55AM	Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down (InvestorPlace)
Apr-04-23 02:47PM	Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound (TipRanks) -7.32%
Mar-14-23 04:05PM	Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 06:33AM	Daily Vickers Top Insider Picks for 03/09/2023 (Argus Research)
Feb-08-23 06:30AM	Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference (GlobeNewswire) -8.79%
Dec-21-22 06:46AM	Daily Vickers Top Buyers & Sellers for 12/21/2022 (Argus Research) +5.33%
Dec-14-22 05:15AM	Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN) (Simply Wall St.)
Dec-07-22 04:01PM	Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress (GlobeNewswire) -6.00%
Nov-28-22 10:37AM	Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth (Simply Wall St.)
Nov-03-22 04:05PM	Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-17-22 04:05PM	Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022 (GlobeNewswire)
06:30AM	Loading…
Sep-22-22 06:30AM	Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Aug-08-22 04:05PM	Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-03-22 06:30AM	Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference (GlobeNewswire) +6.33%
Jun-21-22 09:57AM	Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth (Simply Wall St.) +6.24%
Jun-01-22 06:30AM	Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-09-22 04:05PM	Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results (GlobeNewswire)
Mar-30-22 06:30AM	Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC Molecule for the Treatment of Friedreich Ataxia (GlobeNewswire)
Mar-23-22 02:53PM	Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months (Simply Wall St.)
Mar-10-22 04:02PM	Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-09-22 06:30AM	Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022 (GlobeNewswire) +9.41%
Feb-28-22 04:05PM	Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC Molecule for Friedreich Ataxia (GlobeNewswire)
Feb-10-22 06:30AM	Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire) +7.02%
Feb-01-22 04:05PM	Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer (GlobeNewswire)
Jan-19-22 12:51PM	Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating (Benzinga) -5.86%
Dec-23-21 05:00AM	Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +5.09%
Nov-09-21 04:05PM	Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results (GlobeNewswire)
Sep-24-21 07:55AM	Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months (Simply Wall St.)
Sep-08-21 06:30AM	Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1 (GlobeNewswire)
Sep-03-21 07:33AM	4 Stocks Insiders Are Buying (Benzinga)
Aug-09-21 04:05PM	Design Therapeutics Reports GeneTAC Portfolio Progress and Second Quarter 2021 Results (GlobeNewswire)
Jun-26-21 04:30AM	We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely (Simply Wall St.)
Jun-07-21 04:10PM	Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Design Therapeutics Expands Board of Directors with Key Appointments (GlobeNewswire)
May-10-21 04:05PM	Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results (GlobeNewswire)
Mar-30-21 04:05PM	Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -13.20%
Mar-25-21 11:56PM	Design Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schmid John P.	Director	Mar 25 '24	Buy	3.74	17,809	66,606	26,965	Mar 25 07:10 PM
Berger Heather A.	Director	Mar 25 '24	Buy	3.74	1,300	4,866	1,300	Mar 25 07:09 PM
Schmid John P.	Director	Mar 22 '24	Buy	3.62	9,156	33,133	9,156	Mar 25 07:10 PM
LAPPE RODNEY W	Director	Sep 29 '23	Buy	2.35	21,000	49,287	133,024	Oct 02 06:01 PM
William Arsani	Director	Aug 29 '23	Buy	2.44	1,960,000	4,782,400	3,000,000	Aug 30 06:02 PM
Prasad Deepa	Director	Aug 29 '23	Buy	2.31	12,000	27,670	23,806	Aug 30 06:06 PM
William Arsani	Director	Aug 28 '23	Buy	2.15	275,000	591,250	1,040,000	Aug 30 06:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DSGN

Design Therapeutics Inc

Upgrade your FINVIZ experience